The Phase 3 “AFFIRM” clinical study evaluates Gene Biotherapeutics’ lead product candidate, Generx [Ad5FGF-4], as a one-time administration for the treatment of refractory angina due to late-stage coronary artery disease.
Gene Biotherapeutics’ angiogenic gene therapy is designed to improve cardiac perfusion (blood flow) and to increase the supply of oxygenated blood by promoting the growth of microvasculature in ischemic cardiac tissue.
Generx [Ad5FGF-4] is engineered to express secreted human fibroblast growth factor-4 (FGF-4) protein, a key regulator of angiogenesis. Generx is administered by an interventional cardiologist during a brief procedure similar to a diagnostic angiogram.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.